ALK and non-small cell lung carcinoma: Similarly, in an exploratory analysis of 2 trials of brigatinib for ALK-positive NSCLC, the objective response rates were 53, 46, and 67%, in patients with measurable brain metastases, from the phase I/II study, ALTA arm A (brigatinib 90 mg daily), and ALTA arm B (brigatinib 180 mg daily), respectively (18).